LYEL Insider Trading

Lyell Immunopharma, Inc. (LYEL) operates in the Healthcare sector, specifically the Biotechnology industry, with a market capitalization near $184.0M, listed on NASDAQ, employing roughly 161 people, carrying a beta of -0.07 to the broader market. Lyell Immunopharma, Inc. Led by Lynn Seely, public since 2021-06-17.

In the last 12 months, Lyell Immunopharma, Inc. insiders made 2 buy transactions and 29 sale transactions.

DateNameTypeSharesPriceValue
Oct 13, 2026Aguirre Jarrad MattieuS-Sale422$8.63$3.6K
Sep 10, 2026Shook DavidS-Sale500$12.70$6.3K
Sep 10, 2026Aguirre Jarrad MattieuA-Award47,500$12.20$579.5K
Sep 10, 2026Aguirre Jarrad Mattieu0$0.00$0
Sep 10, 2026Aguirre Jarrad Mattieu46,249$11.64$538.3K
Sep 10, 2026Aguirre Jarrad Mattieu35,000$23.71$829.9K
Sep 10, 2026Aguirre Jarrad Mattieu15,000$19.20$288.0K
Aug 25, 2026Seely LynnS-Sale9,589$15.54$149.0K
Aug 25, 2026Hill Stephen J.S-Sale989$15.54$15.4K
Aug 25, 2026Lee Gary K.S-Sale1,457$15.54$22.6K

LYEL Insider Activity by Quarter

Reported Form 4 and Form 5 lines under LYEL's own SEC company ID, by transaction date, back to Q4 2024. Purchases and sales are code P / S (open market or private) in the company's shares; other lines are purchases and sales of other securities (options, warrants, preferred), awards, exercises, tax withholding, gifts and other acquisitions and dispositions. Later filings and amendments can change the current quarter. Earlier quarters are not shown: the filings read reach back to Jun 17, 2021, and a quarter counts only when every filing for it was read.

QuarterPurchasesBoughtSalesSoldOther Lines
Q4 2026 (so far)0N/A1$3.6K0
Q3 20260N/A10$211.3K3
Q2 20260N/A5$40.6K9
Q1 20262$25.0M7$264.3K10
Q4 20250N/A6$88.4K3
Q3 20250N/A12$133.6K4
Q2 20250N/A0N/A10
Q1 20255$447.9K0N/A15
Q4 20240N/A0N/A1

LYEL Institutional Ownership (13F)

As of Jun 30, 2026 (Q2 2026), 87 institutions reported holding 12,674,436 LYEL shares, valued at $178.0M as reported, 70.1% of its market cap (market cap of Jun 26, 2026). That is +13 institutions from the quarter before. Among managers whose reports for both quarters are comparable, 23 opened a position, 9 closed one, 28 added and 19 trimmed.

Top Holders, Q2 2026

ManagerSharesValueChange
ARCH Venture Management, LLC3,247,162$45.5MUnchanged
GSK plc1,512,659$21.3MUnchanged
VANGUARD CAPITAL MANAGEMENT LLC786,774$11.1M+68,619
Orland Properties Ltd754,698$10.6MUnchanged
BlackRock, Inc.724,342$10.2M+532,522
Decheng Capital LLC692,050$9.7MUnchanged
Almitas Capital LLC581,407$8.2M+3,600
Foresite Capital Management V, LLC476,386$6.7M-692
MILLENNIUM MANAGEMENT LLC367,473$5.2M-91,432
Opaleye Management Inc.344,025$4.8M+264,928

By Quarter

QuarterInstitutionsSharesValue
Q2 20268712,674,436$178.0M
Q1 20267412,666,595$251.1M
Q4 20256912,180,020$374.2M
Q3 20255910,878,740$174.3M
Q2 2025*699,259,424$81.9M
Q1 2025113152,406,913$81.8M
Q4 2024105150,311,098$95.9M
Q3 2024117128,510,690$176.7M
Q2 2024119133,926,970$194.8M

* Q2 2025: 1 with shares on another basis (not in the shares).

From the SEC's Form 13F data sets: investment managers with $100 million or more in Section 13(f) securities report their holdings each quarter, up to 45 days after it ends; a restated filing replaces the original, and values are as the managers reported them (a position whose price runs about 1,000 times below other managers', from a manager whose positions mostly do, is read as reported in thousands of dollars). The same shares can be reported by more than one manager, so totals can count some twice.

ETFs Holding LYEL

FundWeight of LYELShares (as reported)Value (as reported)Source updated
IWM iShares Russell 2000 ETF0.00%231,351$2.0MOct 8, 2026
IBB iShares Biotechnology ETF0.00%57,947$496.0KOct 8, 2026
SCHA Schwab U.S. Small-Cap ETF0.00%56,382$478.9KOct 8, 2026
IWC iShares Micro-Cap ETF0.02%26,691$228.5KOct 8, 2026
AVSC Avantis U.S. Small Cap Equity ETF0.01%23,990$205.4KOct 8, 2026
SCHB Schwab U.S. Broad Market ETF0.00%9,101$78.2KOct 8, 2026
PRFZ Invesco RAFI US 1500 Small-Mid ETF0.00%8,809$75.4KOct 8, 2026
RSSL Global X - Russell 2000 ETF0.00%4,501$38.8KOct 7, 2026
DCOR U.S. Core Equity 1 Portfolio ETF Class Shares0.00%1,961$16.9KOct 8, 2026
DXUV U.S. Vector Equity Portfolio ETF Class Shares0.00%1,896$16.3KOct 8, 2026
IBBQ Invesco Nasdaq Biotechnology ETF0.01%1,749$15.0KOct 8, 2026
BIB ProShares Ultra Nasdaq Biotechnology0.01%863$7.4KOct 8, 2026
ITWO ProShares Russell 2000 High Income ETF0.00%495$4.2KOct 8, 2026
DFAC Dimensional - US Core Equity 2 ETF0.00%409$3.5KOct 8, 2026
URTY ProShares - UltraPro Russell20000.00%348$3.0KOct 8, 2026

From each fund's latest holdings file on record that shows LYEL's listed security itself. A file counts when its line count is consistent with the fund's reported holdings count (at most twice it plus 10, or at most 1,000 lines for a reported count of exactly 10, which the data source gives many funds as a cap), read with that file or inherited from the fund's last classified file (within 20% of its line count, read within 60 days). Funds whose line for the company could not be confirmed as LYEL's listed security, or that hold it through underlying funds (look-through), are not listed. Only long positions count: a fund is left out when any of its lines for LYEL reports a negative weight, share count or value, or none of them above zero (a short position, or figures that disagree). Shares, value and weight are as reported in each fund's file, dated by the data source's last update of that file (not the date of the positions); the weight is LYEL's share of that fund.

How to Read LYEL Insider Activity

Net insider sentiment skews to the sell side over the trailing twelve months: 29 sales versus 2 buys. Insider sales carry less informational weight than buys because they are often driven by liquidity, tax planning, or pre-scheduled Rule 10b5-1 trading plans rather than negative information. The transaction type alone does not say whether a sale was made on the open market or privately, or under a 10b5-1 plan; the filing's plan checkbox and footnotes do. The transaction table above includes the filer's reporting name, transaction type, share count, per-share price, and total dollar value where computable. For options traders, insider activity is one input to event-driven sizing alongside earnings calendar, analyst-rating cluster moves, and the implied-vol surface. Form 4 filings (the dominant Section 16 reporting form) must be submitted within two business days of the transaction; clusters of buys across multiple insiders within a short window are the strongest informational pattern. SEC EDGAR carries the underlying source filings for verification and additional historical depth.

Learn how insider trading is reported and how to read the data →

Frequently asked LYEL insider trading questions

How active are LYEL insiders right now?
Over the trailing twelve months, Lyell Immunopharma, Inc. (LYEL) insiders made 2 buy transactions and 29 sale transactions. Net insider sentiment over the trailing twelve months tilts to the sell side (29 sales vs 2 buys). The transaction list above shows the most recent filings; each entry includes the insider's name, transaction type, share count, and per-share price.
What counts as an insider transaction?
Section 16 of the Securities Exchange Act requires officers, directors, and 10% beneficial-owner shareholders to disclose changes in their holdings via Form 3 (initial statement), Form 4 (subsequent transactions, filed within two business days), and Form 5 (annual catch-up). Insider transactions cover open-market purchases and sales, exercise of stock options, gifts, and grants. The "transaction type" field on each row distinguishes these subcategories.
Are LYEL insider buys a bullish signal?
Insider purchases (Type P, made on the open market or privately; the code covers both) carry more informational weight than insider sales: an insider must commit personal capital, and the SEC scrutinizes purchases under Rule 10b5-1 for material non-public information. Sales, by contrast, are often driven by liquidity, tax planning, or pre-scheduled 10b5-1 trading plans rather than negative information. Cluster buying (multiple insiders buying within a short window) is a stronger signal than isolated buys.
How do LYEL insider transactions affect options pricing?
Insider transaction data does not directly drive implied volatility, but Form 4 disclosures can move single-name IV if the size or timing is unusual (e.g. a large CEO buy ahead of an earnings window). Options markets price the marginal informational content; routine transactions under pre-scheduled plans are typically ignored. For event-driven options sizing, pair the insider transaction history with the upcoming earnings calendar.